{"id":1126681,"date":"2026-08-02T21:40:20","date_gmt":"2026-08-02T21:40:20","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/1126681\/"},"modified":"2026-08-02T21:40:20","modified_gmt":"2026-08-02T21:40:20","slug":"astrazeneca-and-bristol-myers-squibb-mull-400-billion-deal-report","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/1126681\/","title":{"rendered":"AstraZeneca and Bristol Myers Squibb mull $400 billion deal: Report"},"content":{"rendered":"<p>A smart acquisition strategy has made Bristol-Meyers, which has bought seven companies since October 2007, a big player in the cancer-treatment industry. Its purchase of Medarex in July added a key drug for metastic melanoma that\u2019s in Phase III trials. The drug has possible multiple indications \u2013 industry jargon for its ability to treat more than one condition \u2013 for lung and prostate cancer.But BMY also sells Erbitux for colorectal, head and neck cancer, Ixempra for breast cancer, Taxol for brea<\/p>\n<p><img decoding=\"async\" class=\"InlineVideo-videoThumbnail\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2026\/08\/108340298-17851337761785133772-47411763109-1080pnbcnews.jpg\" alt=\"AstraZeneca CFO: Very confident we will hit $80 billion revenue target\"\/><a href=\"https:\/\/www.google.com\/preferences\/source?q=https:\/\/www.cnbc.com\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"A smart acquisition strategy has made Bristol-Meyers, which has bought seven companies since October 2007, a big player&hellip;\n","protected":false},"author":2,"featured_media":1126682,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[8818],"tags":[30888,24576,381,20951,748,51,3085,393,31702,4884,20944,306718,228645,6316,5489,61686,16,15,49],"class_list":["post-1126681","post","type-post","status-publish","format-standard","has-post-thumbnail","category-bristol","tag-astrazeneca-plc","tag-biotech-and-pharmaceuticals","tag-bristol","tag-bristol-myers-squibb-co","tag-britain","tag-business","tag-business-news","tag-england","tag-gilead-sciences-inc","tag-great-britain","tag-health-care-industry","tag-invesco-pharmaceuticals-etf","tag-ishares-u-s-pharmaceuticals-etf","tag-mergers-and-acquisitions","tag-pharmaceuticals","tag-spdr-sp-biotech-etf","tag-uk","tag-united-kingdom","tag-united-states"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/117028090567443302","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1126681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=1126681"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1126681\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/1126682"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=1126681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=1126681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=1126681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}